MTOR and lymphangioleiomyomatosis: These signaling changes are in agreement with previous findings in LAM cells, specifically that a TSC2 loss or mutation leads to disruption of the tuberin-hamartin heterodimer resulting in activation of the mTOR signaling pathway, and dysregulation of S6K1 activation.